Gene · 51185
Papers2,935
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
501 to 520 of 2,935
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Recent advancements in targeted protein knockdown technologies-emerging paradigms for targeted therapy. | Explor Target Antitumor Ther | 2023 | 38213543 | PubTator, text mining | PubMed |
| Targeting the Ubiquitin-Proteasome System and Recent Advances in Cancer Therapy. | Cells | 2023 | 38201233 | PubTator, text mining | PubMed |
| Biology of Pellino1: a potential therapeutic target for inflammation in diseases and cancers. | Front Immunol | 2023 | 38179042 | PubTator, text mining | PubMed |
| Ubiquitin signaling in pancreatic ductal adenocarcinoma. | Front Mol Biosci | 2023 | 38174069 | PubTator, text mining | PubMed |
| Lenalidomide with or without dexamethasone for relapsed or refractory Hodgkin lymphoma post autologous stem cell transplant. | Blood Cell Ther | 2023 | 38146353 | PubTator, text mining | PubMed |
| Revolutionizing Drug Targeting Strategies: Integrating Artificial Intelligence and Structure-Based Methods in PROTAC Development. | Pharmaceuticals (Basel) | 2023 | 38139776 | PubTator, text mining | PubMed |
| Resisting the Resistance: Navigating BTK Mutations in Chronic Lymphocytic Leukemia (CLL). | Genes (Basel) | 2023 | 38137005 | PubTator, text mining | PubMed |
| Benzothiazole-Phthalimide Hybrids as Anti-Breast Cancer and Antimicrobial Agents. | Antibiotics (Basel) | 2023 | 38136685 | PubTator, text mining | PubMed |
| Recent Advances in Optically Controlled PROTAC. | Bioengineering (Basel) | 2023 | 38135959 | PubTator, text mining | PubMed |
| Cooperatively designed aptamer-PROTACs for spatioselective degradation of nucleocytoplasmic shuttling protein for enhanced combinational therapy. | Chem Sci | 2023 | 38131089 | PubTator, text mining | PubMed |
| Discovery of Ligands for TRIM58, a Novel Tissue-Selective E3 Ligase. | ACS Med Chem Lett | 2023 | 38116426 | PubTator, text mining | PubMed |
| Sequential deregulation of histone marks, chromatin accessibility and gene expression in response to PROTAC-induced degradation of ASH2L. | Sci Rep | 2023 | 38114530 | PubTator, text mining | PubMed |
| Direct-to-biology, automated, nano-scale synthesis, and phenotypic screening-enabled E3 ligase modulator discovery. | Nat Commun | 2023 | 38114468 | PubTator, text mining | PubMed |
Immunomodulation of NK, NKT and B/T cell subtypes in relapsed/refractory multiple myeloma patients treated with pomalidomide along with velcade and dexamethasone and its association with improved progression-free survival. | Front Oncol | 2023 | 38111533 | PubTator, text mining | PubMed |
| The involvement of E3 ubiquitin ligases in the development and progression of colorectal cancer. | Cell Death Discov | 2023 | 38104139 | PubTator, text mining | PubMed |
| Discovery of Molecular Glue Degraders via Isogenic Morphological Profiling. | ACS Chem Biol | 2023 | 38098458 | PubTator, text mining | PubMed |
| One-Pot Synthesis of Cereblon Proteolysis Targeting Chimeras via Photoinduced C(sp2)-C(sp3) Cross Coupling and Amide Formation for Proteolysis Targeting Chimera Library Synthesis. | J Med Chem | 2023 | 38096359 | PubTator, text mining | PubMed |
| N-Boc-α-diazo glutarimide as efficient reagent for assembling N-heterocycle-glutarimide diads via Rh(II)-catalyzed N-H insertion reaction. | Beilstein J Org Chem | 2023 | 38090627 | PubTator, text mining | PubMed |
| Structural and biophysical comparisons of the pomalidomide- and CC-220-induced interactions of SALL4 with cereblon. | Sci Rep | 2023 | 38086859 | PubTator, text mining | PubMed |
| Late-stage synthesis of heterobifunctional molecules for PROTAC applications via ruthenium-catalysed C‒H amidation. | Nat Commun | 2023 | 38086825 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/51185/papers?page=26